{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-018093","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.236326+00:00","generated_at":"2026-05-17T03:45:38.293549+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market","bullets":["Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.","Subject to one-year Mandatory Panel Monitor; if equity rule breached, no additional time to regain compliance but hearing available.","Common stock (BIAF) and warrants (BIAFW) continue trading on Nasdaq Capital Market.","CEO Maria Zannes: regaining compliance allows focus on CyPath Lung test and building shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-018093","json":"https://secwatch.observer/filing/0001493152-25-018093.json","markdown":"https://secwatch.observer/filing/0001493152-25-018093.md","text":"https://secwatch.observer/filing/0001493152-25-018093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225018093/0001493152-25-018093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225018093/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:45:38.293549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}